Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Gilead Sciences : Chief Scientific Officer John McHutchison to Leave

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/17/2019 | 09:10am EDT

By Colin Kellaher

Gilead Sciences Inc. (GILD) on Wednesday said three executives, including its top researcher, will be leaving the biopharmaceutical company.

Gilead said John McHutchison is stepping down as chief scientific officer and head of research and development, effective Aug. 2.

The Foster City, Calif., company said it will immediately commence a search for his successor.

Mr. McHutchison, who joined Gilead in 2010 and has been chief scientific officer since March 2018, will receive a lump-sum payment of $1.1 million as part of a transition agreement, the company said.

Separately, Gilead said Chief Patient Officer Gregg Alton and Katie Watson, executive vice president of human resources, will also be leaving the company.

Mr. Alton, who joined Gilead in 1999, will remain through Oct. 4 and will serve as an adviser until the end of the year to help transition his duties to other parts of the company.

Gilead said Jyoti Mehra, who joined the company in 2017 as vice president of human resources, will succeed Ms. Watson as executive vice president of human resources, effective Aug. 5.

Ms. Watson, who joined Gilead in 2003, will leave on Sept. 1 but will advise on the transition through the end of the year, Gilead said.

Write to Colin Kellaher at colin.kellaher@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
08/22GSK's long acting HIV injection gets boost from study
RE
08/21GILEAD SCIENCES : Statement on Petitions to U.S. Patent and Trademark Office on ..
PU
08/19Who is next in big pharma's merger spree?
RE
08/16GILEAD SCIENCES : European Medicines Agency Validates Marketing Application for ..
AQ
08/15European Medicines Agency Reviews Arthritis Treatment by Gilead, Galapagos
DJ
08/15STEALTH BIOTHERAPEUTICS : Reports First Half 2019 Financial Results and Recent B..
AQ
08/15GILEAD SCIENCES : Québec Provides Access to Biktarvy® for the Treatment of HIV
AQ
08/13GILEAD SCIENCES : Report
CO
08/12GILEAD SCIENCES : China National Medical Products Administration Approves Biktar..
AQ
08/12GILEAD SCIENCES : China National Medical Products Administration Approves Biktar..
AQ
More news
Financials (USD)
Sales 2019 22 314 M
EBIT 2019 11 591 M
Net income 2019 4 273 M
Debt 2019 3 023 M
Yield 2019 4,03%
P/E ratio 2019 17,8x
P/E ratio 2020 10,9x
EV / Sales2019 3,68x
EV / Sales2020 3,54x
Capitalization 79 166 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 80,39  $
Last Close Price 62,51  $
Spread / Highest target 52,0%
Spread / Average Target 28,6%
Spread / Lowest Target -4,02%
EPS Revisions
Managers
NameTitle
Gregg H. Alton Chief Executive & Patient Officer
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
John G. McHutchison Chief Scientific Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES-0.06%81 332
VERTEX PHARMACEUTICALS8.73%47 356
REGENERON PHARMACEUTICALS-23.20%32 282
GENMAB29.13%13 323
NEUROCRINE BIOSCIENCES, INC.36.66%8 905
BEIGENE LTD--.--%8 692